BALA CYNWYD, Pa. -- (Business Wire)

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Inspire Pharmaceuticals, Inc. (“Inspire” or the “Company”) (Nasdaq - ISPH) relating to the proposed acquisition by Merck & Co. (“Merck”).

Under the terms of the transaction, Inspire shareholders would receive $5.00 in cash for each share of common stock they own. The proposed transaction has an approximate value of $430 million. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Inspire by not acting in Inspire shareholders' best interests in connection with the sale process to Merck. The transaction may undervalue Inspire as Inspire stock traded at $8.40 as recently as December 31, 2010 and an analyst placed a $10.00 price target on the stock.

If you own shares of Inspire stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, visiting http://brodsky-smith.com/274-isph-inspire-pharmaceuticals-inc.html, or by calling toll free 877-LEGAL-90.

Contacts:

Brodsky & Smith, LLC
Jason L. Brodsky, Esquire
Evan J. Smith, Esquire
877-LEGAL-90
investorrelations@brodsky-smith.com
http://brodsky-smith.com/274-isph-inspire-pharmaceuticals-inc.html

Source: Brodsky & Smith, LLC